Denali Therapeutics’ (DNLI) “Outperform” Rating Reiterated at William Blair

William Blair restated their outperform rating on shares of Denali Therapeutics (NASDAQ:DNLI) in a research note released on Friday morning,RTT News reports.

A number of other equities research analysts have also weighed in on DNLI. JPMorgan Chase & Co. reduced their target price on shares of Denali Therapeutics from $28.00 to $24.00 and set an “overweight” rating on the stock in a report on Tuesday, January 7th. Jefferies Financial Group boosted their price objective on shares of Denali Therapeutics from $40.00 to $45.00 and gave the stock a “buy” rating in a research note on Friday, November 1st. Deutsche Bank Aktiengesellschaft started coverage on Denali Therapeutics in a research report on Tuesday, February 11th. They set a “buy” rating and a $31.00 target price for the company. The Goldman Sachs Group lowered their price target on shares of Denali Therapeutics from $45.00 to $40.00 and set a “buy” rating for the company in a report on Tuesday, January 28th. Finally, HC Wainwright boosted their price objective on Denali Therapeutics from $80.00 to $87.00 and gave the company a “buy” rating in a research note on Friday. Two research analysts have rated the stock with a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus target price of $37.42.

Denali Therapeutics Stock Down 11.0 %

NASDAQ DNLI opened at $16.56 on Friday. Denali Therapeutics has a twelve month low of $14.56 and a twelve month high of $33.33. The business’s fifty day moving average is $21.38 and its 200 day moving average is $24.59. The company has a market cap of $2.38 billion, a price-to-earnings ratio of -6.00 and a beta of 1.43.

Denali Therapeutics (NASDAQ:DNLI) last announced its quarterly earnings results on Thursday, February 27th. The company reported ($0.67) EPS for the quarter, beating analysts’ consensus estimates of ($0.75) by $0.08. On average, research analysts anticipate that Denali Therapeutics will post -2.71 earnings per share for the current fiscal year.

Insider Activity at Denali Therapeutics

In related news, Director Steve E. Krognes sold 3,339 shares of the stock in a transaction that occurred on Tuesday, January 7th. The stock was sold at an average price of $20.81, for a total transaction of $69,484.59. Following the completion of the sale, the director now directly owns 25,757 shares of the company’s stock, valued at approximately $536,003.17. This trade represents a 11.48 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Ryan J. Watts sold 29,266 shares of Denali Therapeutics stock in a transaction on Monday, January 6th. The stock was sold at an average price of $20.22, for a total value of $591,758.52. Following the sale, the chief executive officer now owns 260,721 shares in the company, valued at $5,271,778.62. This trade represents a 10.09 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 47,940 shares of company stock valued at $973,442 over the last ninety days. Corporate insiders own 7.90% of the company’s stock.

Institutional Trading of Denali Therapeutics

A number of large investors have recently added to or reduced their stakes in the stock. Victory Capital Management Inc. boosted its stake in Denali Therapeutics by 163.7% in the third quarter. Victory Capital Management Inc. now owns 39,900 shares of the company’s stock valued at $1,162,000 after acquiring an additional 24,767 shares during the last quarter. FMR LLC raised its holdings in shares of Denali Therapeutics by 3,234.3% in the 3rd quarter. FMR LLC now owns 7,831,378 shares of the company’s stock worth $228,128,000 after purchasing an additional 7,596,508 shares during the period. Algert Global LLC grew its holdings in Denali Therapeutics by 82.4% during the third quarter. Algert Global LLC now owns 48,630 shares of the company’s stock valued at $1,417,000 after purchasing an additional 21,975 shares during the period. JPMorgan Chase & Co. increased its position in Denali Therapeutics by 6.5% in the third quarter. JPMorgan Chase & Co. now owns 235,386 shares of the company’s stock worth $6,857,000 after buying an additional 14,324 shares during the last quarter. Finally, Principal Financial Group Inc. increased its position in Denali Therapeutics by 13.8% in the third quarter. Principal Financial Group Inc. now owns 1,238,476 shares of the company’s stock worth $36,076,000 after buying an additional 149,939 shares during the last quarter. Hedge funds and other institutional investors own 92.92% of the company’s stock.

About Denali Therapeutics

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.